Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults - Contacts and Locations

Immunogenicity, Safety and Tolerability of the Typhoid Fever Vaccine Candidate M01ZH09 in Healthy Adults

This study is currently recruiting participants.

Study NCT00679172. Last updated on July 25, 2008. Information provided by Emergent BioSolutions

Please refer to this study by its ClinicalTrials.gov identifier: NCT00679172

Contacts


Contact: Ron Budhram	+44 (0)118 944 3300	clindev@ebse.com

Locations


United States, Florida
	Miami Research Associates	Recruiting
	South Miami, Florida, United States, 33143
	Contact: Eric Sheldon 305-279-0015 ext 4223 esheldon@miamiresearch.com
	Principal Investigator: Eric Sheldon

United States, Maryland
	John Hopkins Bloomberg School of Public Health	Recruiting
	Baltimore, Maryland, United States, 21205
	Contact: Clayton Harro 410-614-4937 charro@jhsph.edu
	Principal Investigator: Clayton Harro

United States, Vermont
	Unit of Infectious Diseases, University of Vermont College of Medicine	Recruiting
	Burlington, Vermont, United States, 05405
	Contact: Beth Kirkpatrick 802-656-5822 Beth.kirkpatrick@uvm.edu
	Principal Investigator: Beth Kirkpatrick

Sponsors and Collaborators

Emergent BioSolutions

Investigators


Study Director:	Stephen Lockhart, DM	Emergent BioSolutions